MicroRNA-26a-5p as a potential predictive factor for determining the effectiveness of trastuzumab therapy in HER-2 positive breast cancer patients

BACKGROUND: Breast cancer (BC) is known as the most prevalent type of cancer among women. Trastuzumab, as an anticancer drug, has been used broadly in human epidermal growth factor receptor 2 (HER-2) positive (+) BC patients. Moreover, accumulating evidence has demonstrated that microRNAs is involve...

Descripción completa

Detalles Bibliográficos
Autores principales: Tehrani, Sadra Samavarchi, Zaboli, Ehsan, Sadeghi, Farzin, Khafri, Soraya, Karimian, Ansar, Rafie, Mahnoosh, Parsian, Hadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: China Medical University 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824250/
https://www.ncbi.nlm.nih.gov/pubmed/35223402
http://dx.doi.org/10.37796/2211-8039.1150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824250/
https://www.ncbi.nlm.nih.gov/pubmed/35223402
http://dx.doi.org/10.37796/2211-8039.1150

Ejemplares similares